Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

The shares closed down nearly 12% after CVS Health's revelation and Lilly's announcement that, despite a 45% surge in first-quarter revenues driven by Zepbound (tirzepatide) and diabetes ...

Meanwhile, the Danish drugmaker was also bolstered by the decision by pharmacy benefit manager (PBM) CVS Health to remove Zepbound but retain Wegovy on its formulary of reimbursed medicines.

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...